New research reveals that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who end conventional lifestyle programs.
Research printed in a prominent health publication points out that while obese people often shed substantial amounts of their body weight while on the medication, the weight returns at an average rate of nearly a kilo each month upon discontinuation.
"Individuals buying these treatments must be cognizant of the risk of fast weight regain when the treatment is stopped," cautioned researcher Dr. Susan Jebb.
This pace of recovery implies a reversion to pre-treatment weight in about 18 months.
Analyzing Approaches
The study, which examined 37 of trials involving thousands of participants, compared the outcomes of the injectable medications with conventional dieting.
Scientists point out that people who shed pounds through dieting generally see a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
Understanding the Quick Rebound
Experts believe the way of the drugs is key to understanding the heightened rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which controls appetite.
"Artificially providing GLP-1 concentrations several times higher than normal may cause the body to produce less of its own natural GLP-1, and could diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement leads to hunger is uncontrolled, making binge eating much more probable."
A Chronic Issue?
Health authorities suggest the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians argue that, given the significant potential of relapse, the treatment is often long-term.
This perspective is reinforced by drug manufacturers, who note that the results "underscore the persistent character of excess weight," akin to managing diseases like high blood pressure.
Patient Accounts
Users who have come off the jabs describe a sudden return of hunger.
"It felt as if something that goes on and you're instantly starving," described an individual.
This difficulty is compounded if patients have not developed permanent lifestyle or habit changes during therapy.
Significant Adoption
Recent estimates indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Adoption is higher among women than men.
- The 40s and 50s age group shows the highest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, experts stress that while GLP-1 drugs are effective agents for shedding pounds, they are not a magic solution and long-term success hinges on combined behavioural changes.
